References
- 1. ASRANI S., DEVARBHAVI H., EATON J., KAMATH P. Burden of liver diseases in the world. J Hepatol. 2019; 70(1):151–171.
- 2. PIMPIN L., CORTEZ-PINTO H., NEGRO F. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718–735.
- 3. CHEDID, M. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA. Dig Dis Sci. 2017; 62:2621–2622.
- 4. DOYCHEVA I., WATT K., RIFAI G. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017; 62(5):1373–1380.
- 5. HEIDELBAUGH J., BRUDERLY M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74(5):756–762.
- 6. YOUNOSSI Z., STEPANOVA M., YOUNOSSI Y., GOLABI P., MISHRA A., RAFIQ N., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020; 69:564–568.
- 7. SCHIERWAGEN R., USCHNER F., MAGDALENO F., KLEIN S.,TREBICKA J. Rationale for the use of statins in liver disease. Am J Physiol Liver Physiol. 2017; 312:407–412.
- 8. MOCTEZUMA-VELAZQUEZ C., ABRALDES J., MONTANO-LOZA A. The Use of Statins in Patients with Chronic Liver Disease. Curr Treat Options Gastro. 2018; 16:226–240.
- 9. VARGAS J., ARRESE M., SHAH V., ARAB J. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep. 2017; 19(9):43.
- 10. JANICKO M., DRAZILOVA S., PELLA D., FEDACKO J., JERCUSKA P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016; 22(27):6201–6213.
- 11. KUMAR S., GRACE N., QAMAR A. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. Dig Dis Sci. 2104; 59:1958–1965.
- 12. SAKAMOTO K., KIMURA J. Mechanism of Statin-Induced Rhabdomyolysis. J Pharmacol Sci. 2013; 123:289–294.
- 13. FARIGON, S., PORZIO, M., FRACANZANI A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37)13306–13324.
- 14. DONGIOVANNI P., PETTA A., MANNISTRO V., MANCINA R., PIPITONE R., VALENTI L., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015; 63:705–712.
- 15. IKEDA M., ABEK., YAMADA M., DANSAKO H., KATO N. Different anti-HCV profiles for statins and their potential for combination therapy with interferon. Hepatology. 2006; 44(1):117–125.
- 16. ABRALDES, J., VILLANUEVA C., ARACIL C., TURNES J., HERNANDEZ-GUERRA M., et a;. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016; 150:1160–1170.
- 17. SIMON T., BONILLA H., CHUNG R., BUTT A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients hepatitis c virus: results from ERCHIVES. Hepatology. 2016; 64(1):47–57.
- 18. KAWATA S., YAMASAKI E., NAGASE T., INUI Y., ITO N., MATSUDA Y., et al. Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. A Randomized Control Trial.Br J Cancer. 2001; 84:886–891.
- 19. CONNOLLY S. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100(19):2025.
- 20. BABATIN, M., LEE S., POLLAK P. Amiodarone Hepatotoxicity. Current Vascular Pharmacology. 2008; 6:228–236.
- 21. POLLACK P., BOUILLON T., SHAFER S. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 200; 67:642–652.
- 22. MATTAR W., GADUS-PIZLO I., KWO P. Amiodarone Hepatotoxicity in the Context of the Metabolic Syndrome and Right-sided Heart Failure. Gastrointestin Liver Dis. 2009; 18(4):419–423.
- 23. PENDYALA V. A case of Amiodarone-induced Hepatitis and Review of the Literature. J Hepatol Gastroint Dis. 2016; 2:120.
- 24. SUNG P., YOON S. Amiodarone Hepatotoxicity. Hepatology. 2012; 1:326.
- 25. LEWIS J., RANARD R., CARUSO A., JACKSON L., MULLICK F., ISHAK K., et al. Amiodarone hepatotoxicity: prevalence and clincopathologic correlations among 104 patients. Hepatology. 1989; 9:679–685.
- 26. ATIQ M., DAVIS J., LAMPS L., BLENAD S., ROSE L. Amiodarone induced liver cirrhosis, Report of two cases. J Gastrointestin Liver Dis. 2009; 18:233–235.
- 27. GOLDSCHLAGER N., EPSTEIN A., NACCARELLI G., OLSHANSKY B., SINGHB. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000; 160:1741–1748.
- 28. KUM L., CHAN W., HUI H., WONG G., HO S., SANDERSON J., et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese Patients with or without baseline liver dysfunction. Clin Cardiol. 2006; 29:295–299.
- 29. TRIPODI A., MUNUCCIP. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147–156.
- 30. QAMAR A., VADUGANATHAN M., GREENBERGER N., GIUGLIANO R. Oral anticoagulants in patients with liver disease. JAM Coll Cardiol. 2018; 71(19)2162–2175.
- 31. LING K., CHAO T., LIU C., LIN Y., CHANG S., LO L., HU Y., TUAN, T., et al. Liver cirrhosis in patient with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Herat Assoc. 2017; 6(6).
- 32. GORIACKO P. VELTRI K. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018; 100(5):488–493.
- 33. HUM J., SHATZEL J., JOU J., DELOUGHERY T. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017; 98:393–397.
- 34. INTAGLIATA N., HENRY Z., MAITLAND H., SHAH N., MATILANDS H., SHAH N., ARGO C., NORTHUP P., CALDWELL S. Direct oral anticoagulants in cirrhosis patient pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016; 61:1721–1727.
- 35. MALESPIN M. Risk of nonsteroidal anti-inflammatory drugs and safety of acetaminophen in patients with advanced liver disease. Clin Liver Dis. 2018; 12(3):85–88.
- 36. CHANDOK N., WATT K. Pain management in the cirrhotic patient: The clinical challenge. Mayo Clin Proc. 2010; 85(5):451–458.
- 37. Eliquis (apixaban) [package insert]. Bristol-Myers Squibb. New York, NY; 11/2019. [cited May 14/2020]. Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf.
- 38. Pradaxa (dabigatran etexilate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT; 11/2019 [cited May 14, 2020]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
- 39. Savaysa (edoxaban) [package insert]. Daiichi Sankyo. Tokyo, Japan. 1/2015 [cited May 14/2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
- 40. Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc. Titusville, NJ; 03/2020 [cited May 14/2020]. Available from: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.